Pharmaceutical

Arrowhead and Sarepta link for rare genetic disease treatments

Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.

Nov 27, 2024 - 06:00
Arrowhead and Sarepta link for rare genetic disease treatments
Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease treatments.
Read the original article

Tags:

Previous Article

Jazz’s HER2 Bispecific Gets FDA Green Light

Next Article

NHS rolls out monoclonal antibody treatment for rare bone disease  

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Eli Lilly’s Mounjaro succeeds in second weight loss study, paving way for FDA review

STAT+: Eli Lilly’s Mounjaro succeeds in second weight l...

Apr 27, 2023

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate ris...

May 9, 2023

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

FDA $7bn plans for 2024: disclose contract manufacturer...

Mar 31, 2023